Heritage of Afluria^®

CSL Biotherapies is a subsidiary of CSL Limited, which operates one of the world’s largest influenza manufacturing facilities for supply to global markets. CSL Limited has more than 90 years of experience in developing and manufacturing vaccines, with nearly 40 years experience in influenza vaccines.

Delivering vaccines is our mission; protecting lives, our passion.

Our long heritage underpins the company’s strong commitment to safety, quality, and reliability. For more details on the company, its history, its products, and its worldwide operations, visit www.csl.com.au.

Afluria^® Influenza Virus Vaccine – a new flu vaccine from a reliable source.

At CSL Biotherapies:

We have been making flu vaccines consistently for 40 years
Our flu vaccines are licensed and sold in 16 countries
We supply the antigen for vaccine in 24 countries

Reliable Supplier

Reliable availability throughout the flu season.

Go Now >

CSL Biotherapies History

A trusted influenza vaccine manufacturer with 40 years experience.

Go Now >

A Season Ahead

Our flu vaccine experience in the southern hemisphere influences our readiness in the northern hemisphere.

Go Now >

Important Safety Information

Afluria^® is indicated for active immunization of persons 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria^®; no controlled clinical studies have demonstrated a decrease in influenza disease after vaccination with Afluria^®.

Afluria^® should not be administered to individuals with hypersensitivity to eggs or chicken protein or other components of Afluria^®, or to anyone who has had a life-threatening reaction to previous influenza vaccination. The most common injection-site adverse reactions were tenderness, pain, redness, and swelling. The most common systemic adverse reactions were headache, malaise, and muscle aches.

Vaccination with Afluria^® may not protect all individuals. Immunocompromised persons may have a diminished immune response. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give Afluria^® should be based on careful consideration of the potential benefits and risks.

Click here for full PRESCRIBING INFORMATION.

Heritage of Afluria®

Delivering vaccines is our mission; protecting lives, our passion.

Reliable Supplier

CSL Biotherapies History

A Season Ahead

Heritage of Afluria^®